{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:29:18Z","timestamp":1761175758688,"version":"build-2065373602"},"reference-count":24,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Alzheimer\u2019s disease is the most common neurodegenerative dementia disorder and is associated with several negative health outcomes. Current treatment consists of symptomatic treatment and supportive measures. However, advances have led to the development of antibodies towards beta-amyloid, which likely plays a pivotal role in the pathophysiology. Lecanemab and donanemab have shown efficacy in the early stages of Alzheimer\u2019s disease but are also associated with a risk of cerebral haemorrhages and oedema. The introduction of these antibodies will require adjustment of diagnostic and management pathways as discussed in this review.<\/jats:p>","DOI":"10.61409\/v03250217","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:35:03Z","timestamp":1756899303000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Anti-amyloid antibodies for the treatment of early-stage Alzheimer\u2019s disease"],"prefix":"10.61409","author":[{"given":"Kristian Steen","family":"Frederiksen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias Holsey","family":"Gramkow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steen G.","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunhild","family":"Waldemar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"ref0","unstructured":"Nationalt videnscenter for demes. Forekomst af demens i Danmark, 2025. https:\/\/videnscenterfordemens.dk\/da\/forekomst-af-demens-i-danmark (23. jan 2025)"},{"key":"ref1","unstructured":"World Health Organization. World health statistics 2024: monitoring health for the SDGs, sustainable development goals. Geneva, 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240094703 (23. jan 2025)"},{"key":"ref2","unstructured":"Nationalt videnscenter for demens. Udgifter til demens overstiger udgifter til politi og retsv\u00e6sen, 2023. https:\/\/videnscenterfordemens.dk\/da\/nyhed\/udgifter-til-demens-overstiger-udgifter-til-politi-og-retsvaesen (23. jan 2025)"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Huynh TPV, Davis AA, Ulrich JD, Holtzman DM. Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-\u03b2 and other amyloidogenic proteins. J Lipid Res. 2017;58(5):824-836. https:\/\/doi.org\/10.1194\/jlr.R075481","DOI":"10.1194\/jlr.R075481"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimer's Dis. 2022;9(2):197-210. https:\/\/doi.org\/10.14283\/jpad.2022.30","DOI":"10.14283\/jpad.2022.30"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks JD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527. https:\/\/doi.org\/10.1001\/jama.2023.13239","DOI":"10.1001\/jama.2023.13239"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21. https:\/\/doi.org\/10.1056\/NEJMoa2212948","DOI":"10.1056\/NEJMoa2212948"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185. https:\/\/doi.org\/10.1126\/science.1566067","DOI":"10.1126\/science.1566067"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698-712. https:\/\/doi.org\/10.1038\/nrd3505","DOI":"10.1038\/nrd3505"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Hur JY. \u03b3-Secretase in Alzheimer's disease. Exp Mol Med. 2022;54(4):433-446. https:\/\/doi.org\/10.1038\/s12276-022-00754-8","DOI":"10.1038\/s12276-022-00754-8"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development pipeline: 2023. Alzheimers Dement Transl Res Clin Interv. 2023;9(2):e12385. https:\/\/doi.org\/10.1002\/trc2.12385","DOI":"10.1002\/trc2.12385"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Mantile F, Prisco A. Vaccination against \u03b2-amyloid as a strategy for the prevention of Alzheimer's disease. Biology (Basel). 2020;9(12):425. https:\/\/doi.org\/10.3390\/biology9120425","DOI":"10.3390\/biology9120425"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-\u03b2 load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363-372. https:\/\/doi.org\/10.1016\/S1474-4422(10)70043-0","DOI":"10.1016\/S1474-4422(10)70043-0"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Greenberg SM, Bax F, van Veluw SJ. Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms. Nat Rev Neurol. 2025;(4):193-203. https:\/\/doi.org\/10.1038\/s41582-024-01053-8","DOI":"10.1038\/s41582-024-01053-8"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer's disease. Ageing Res Rev. 2021;68:101339. https:\/\/doi.org\/10.1016\/j.arr.2021.101339","DOI":"10.1016\/j.arr.2021.101339"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Jeremic D, Navarro-L\u00f3pez JD, Jim\u00e9nez-D\u00edaz L. Efficacy and safety of anti-amyloid-\u03b2 monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis. Ageing Res Rev. 2023;90:102012. https:\/\/doi.org\/10.1016\/j.arr.2023.102012","DOI":"10.1016\/j.arr.2023.102012"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Ackley SF, Wang J, Chen R, Power MC, Allen IE, Glymour MM. Estimated effects of amyloid reduction on cognitive change: A Bayesian update across a range of priors. Alzheimers Dement. 2024;20(2):1149-55. https:\/\/doi.org\/10.1002\/alz.13470","DOI":"10.1002\/alz.13470"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Grimm HP, Schumacher V, Sch\u00e4fer M, Imhof-Jung S, Freskg\u00e5rd PO, Brady K, et al. Delivery of the BrainshuttleTM amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. MAbs. 2023;15(1):2261509. https:\/\/doi.org\/10.1080\/19420862.2023.2261509","DOI":"10.1080\/19420862.2023.2261509"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, et al. Clearance mechanisms of Alzheimer's amyloid-\u03b2 peptide: Implications for therapeutic design and diagnostic tests. Mol Psychiatry. 2009;14(5):469-86. https:\/\/doi.org\/10.1038\/mp.2008.96","DOI":"10.1038\/mp.2008.96"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Dickson SP, Wessels AM, Dowsett SA, Mallinckrodt C, Sparks JD, Chatterjee S, et al. \"Time Saved\" as a demonstration of clinical meaningfulness and illustrated using the donanemab TRAILBLAZER-ALZ study findings. J Prev Alzheimers Dis. 2023;10(3):595-9. https:\/\/doi.org\/10.14283\/jpad.2023.50","DOI":"10.14283\/jpad.2023.50"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN, et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE \u03b54\/4) among patients diagnosed with Alzheimer's disease: A systematic review and meta-analysis. Neuroepidemiology. 2012;38(1):1-17. https:\/\/doi.org\/10.1159\/000334607","DOI":"10.1159\/000334607"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Shields LBE, Hust H, Cooley SD, Cooper GE, Hart RN, Dennis BC, et al. Initial experience with lecanemab and lessons learned in 71 patients in a regional medical center. J Prev Alzheimers Dis. 2024;11(6):1549-62. https:\/\/doi.org\/10.14283\/jpad.2024.159","DOI":"10.14283\/jpad.2024.159"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-33. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5","DOI":"10.1016\/S1474-4422(20)30071-5"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Gramkow MH, Waldemar G, Frederiksen KS. The digitized memory clinic. Nat Rev Neurol. 2024;20(12):738-46. https:\/\/doi.org\/10.1038\/s41582-024-01033-y","DOI":"10.1038\/s41582-024-01033-y"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:08:52Z","timestamp":1761124132000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V03250217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":24,"URL":"https:\/\/doi.org\/10.61409\/v03250217","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2025,8,25]]}}}